Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: To assess the effect of tonlamarsen on plasma angiotensinogen (AGT) levels Measure: To assess the systolic blood pressure-lowering effect of tonlamarsen. After: Measure: Part A: To assess variability in clinical and biomarker measures to inform Part B sample-size estimation and study-design assumptions Measure: Part B: To assess the pharmacodynamic (PD) effect of tonlamarsen on plasma AGT levels.
Planned enrollment increased by 40 participants
Before: 100 participants (planned). After: 140 participants (planned).
Primary completion date changed
Before: 29 Dec 2026. After: Dec 2026.